Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $54.96 USD
Change Today +0.03 / 0.05%
Volume 263.8K
NUVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 12:12 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NUVA) Snapshot

Open
$54.90
Previous Close
$54.93
Day High
$55.27
Day Low
$54.73
52 Week High
07/29/15 - $55.66
52 Week Low
10/15/14 - $33.33
Market Cap
2.7B
Average Volume 10 Days
775.1K
EPS TTM
$0.63
Shares Outstanding
48.9M
EX-Date
--
P/E TM
87.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NUVA)

nuvasive inc (NUVA) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NUVA) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NUVA) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $545.7K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $380.5K
President of U.S. Commercial
Total Annual Compensation: $375.0K
Executive Vice President of International and...
Total Annual Compensation: $454.1K
Consultant
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2014.

nuvasive inc (NUVA) Key Developments

NuVasive, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revised Earnings Guidance for 2015

NuVasive, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. The company reported second quarter 2015 total revenue of $202.9 million, a 6.4% increase compared to $190.7 million for the second quarter 2014. On a constant currency basis, second quarter 2015 total revenue increased 8.5% compared to the same period last year. The company reported a GAAP net income attributable to the company of $10.3 million, or $0.20 per diluted share, for the second quarter 2015 compared to a GAAP net loss attributable to the company of $4.1 million, or $0.09 per diluted share, for the second quarter 2014. On a non-GAAP basis, the company reported net income of $15.7 million, or $0.31 per share, for the second quarter 2015 compared to net income of $7.6 million, or $0.15 per share, for the second quarter 2014. Income before income taxes was $18,684,000 compared to loss of $2,328,000 a year ago. Adjusted EBITDA was $50,448,000. For the six months, revenue was $395,293,000 compared to $368,172,000 a year ago. Income before income taxes was $67,966,000 compared to loss of $35,955,000 a year ago. Net income attributable to the company was $41,828,000 or $0.81 per diluted share compared to loss of $22,364,000 or $0.48 per diluted share a year ago. Net cash provided by operating activities was $35,183,000 compared to $48,311,000 a year ago. Purchase of intangible assets was $28,589,000. Purchase of property and equipment was $47,976,000 compared to $32,560,000 a year ago. Non-GAAP earnings were $30,795,000 or $0.61 per share. Adjusted EBITDA was $94,740,000. The company provided the updated projections to its full year 2015 guidance. The company expected revenue of approximately $810.0 million, which includes an approximate $13.0 million of currency headwinds, or approximately 6.2% growth compared to revenue of $762.4 million for 2014; on a constant currency basis revenue is expected to grow approximately 7.9%; versus a prior expectation of 7.8% for 2015; GAAP earnings per share of approximately $1.18 compared to GAAP loss per share of $0.36 for 2014; versus a prior expectation of $1.12 for 2015; Non-GAAP earnings per share of approximately $1.17, an increase of approximately 74.2% compared to non-GAAP earnings of $0.67 for 2014; versus a prior expectation of $1.10 for 2015; Non-GAAP operating margin of approximately 15.0%, an increase of approximately 360 basis points compared to 11.4% for 2014; versus a prior expectation of 14.4% for 2015; adjusted EBITDA margin of approximately 25.2%, an increase of approximately 330 basis points compared to 21.9% for 2014; versus a prior expectation of 24.6% for 2015; GAAP effective tax expense rate of approximately 45.0%; versus a prior expectation of 46.0% for 2015; and non-GAAP effective tax expense rate of approximately 45.0%; versus a prior expectation of 46.0% for 2015.

NuVasive, Inc. Reaches Definitive Settlement with U.S. Department of Justice

NuVasive, Inc. announced that it has reached a definitive settlement with the U.S. Department of Justice related to the subpoena issued to the Company by the Office of Inspector General of the Department of Health and Human Services in 2013. NuVasive admits no wrongdoing as part of the settlement. On April 29, 2015, the company announced that it had reached an agreement in principle to settle the investigation with the DOJ. The Company has now entered into a definitive settlement agreement with the United States, acting through DOJ and on behalf of OIG, the Defense Health Agency, the Office of Personnel Management, and the U.S. Department of Veteran Affairs. Under the terms of the settlement agreement, the company will pay $13.5 million, plus fees and accrued interest. The settlement is neither an admission of liability or wrongdoing by the company nor a concession by the United States that its claims are not well founded.

NuVasive Seeks Acquisitions

NuVasive, Inc. (NasdaqGS:NUVA) announced that it is going to look to use it same penetrate-and-radiate strategy in existing geographies, and evaluate opportunities to be acquisitive in key growth markets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUVA:US $54.96 USD +0.03

NUVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $56.93 USD +0.08
Globus Medical Inc $28.42 USD +0.57
Integra LifeSciences Holdings Corp $64.03 USD +0.03
Masimo Corp $42.03 USD +0.34
Thoratec Corp $63.34 USD +0.05
View Industry Companies
 

Industry Analysis

NUVA

Industry Average

Valuation NUVA Industry Range
Price/Earnings 56.8x
Price/Sales 3.4x
Price/Book 4.0x
Price/Cash Flow 44.9x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.